These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

567 related articles for article (PubMed ID: 26660203)

  • 21. A Phase III, Randomized, Controlled Trial of Apremilast in Patients with Psoriatic Arthritis: Results of the PALACE 2 Trial.
    Cutolo M; Myerson GE; Fleischmann RM; Lioté F; Díaz-González F; Van den Bosch F; Marzo-Ortega H; Feist E; Shah K; Hu C; Stevens RM; Poder A
    J Rheumatol; 2016 Sep; 43(9):1724-34. PubMed ID: 27422893
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Relative efficacy and safety of apremilast, secukinumab, and ustekinumab for the treatment of psoriatic arthritis.
    Song GG; Lee YH
    Z Rheumatol; 2018 Sep; 77(7):613-620. PubMed ID: 28791450
    [TBL] [Abstract][Full Text] [Related]  

  • 23. EULAR recommendations for the management of psoriatic arthritis with pharmacological therapies: 2023 update.
    Gossec L; Kerschbaumer A; Ferreira RJO; Aletaha D; Baraliakos X; Bertheussen H; Boehncke WH; Esbensen BA; McInnes IB; McGonagle D; Winthrop KL; Balanescu A; Balint PV; Burmester GR; Cañete JD; Claudepierre P; Eder L; Hetland ML; Iagnocco A; Kristensen LE; Lories R; Queiro R; Mauro D; Marzo-Ortega H; Mease PJ; Nash P; Wagenaar W; Savage L; Schett G; Shoop-Worrall SJW; Tanaka Y; Van den Bosch FE; van der Helm-van Mil A; Zabotti A; van der Heijde D; Smolen JS
    Ann Rheum Dis; 2024 May; 83(6):706-719. PubMed ID: 38499325
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Efficacy of ustekinumab in biologic-naïve patients with psoriatic arthritis by prior treatment exposure and disease duration: data from PSUMMIT 1 and PSUMMIT 2.
    McInnes IB; Chakravarty SD; Apaolaza I; Kafka S; Hsia EC; You Y; Kavanaugh A
    RMD Open; 2019; 5(2):e000990. PubMed ID: 31565242
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Safety of synthetic and biological DMARDs: a systematic literature review informing the 2013 update of the EULAR recommendations for management of rheumatoid arthritis.
    Ramiro S; Gaujoux-Viala C; Nam JL; Smolen JS; Buch M; Gossec L; van der Heijde D; Winthrop K; Landewé R
    Ann Rheum Dis; 2014 Mar; 73(3):529-35. PubMed ID: 24401994
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Targeted systemic therapies for psoriatic arthritis: a systematic review and comparative synthesis of short-term articular, dermatological, enthesitis and dactylitis outcomes.
    McInnes IB; Sawyer LM; Markus K; LeReun C; Sabry-Grant C; Helliwell PS
    RMD Open; 2022 Mar; 8(1):. PubMed ID: 35321874
    [TBL] [Abstract][Full Text] [Related]  

  • 27. EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs: 2013 update.
    Smolen JS; Landewé R; Breedveld FC; Buch M; Burmester G; Dougados M; Emery P; Gaujoux-Viala C; Gossec L; Nam J; Ramiro S; Winthrop K; de Wit M; Aletaha D; Betteridge N; Bijlsma JW; Boers M; Buttgereit F; Combe B; Cutolo M; Damjanov N; Hazes JM; Kouloumas M; Kvien TK; Mariette X; Pavelka K; van Riel PL; Rubbert-Roth A; Scholte-Voshaar M; Scott DL; Sokka-Isler T; Wong JB; van der Heijde D
    Ann Rheum Dis; 2014 Mar; 73(3):492-509. PubMed ID: 24161836
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Effect of tumour necrosis factor blockers on radiographic progression of psoriatic arthritis: a systematic review and meta-analysis of randomised controlled trials.
    Goulabchand R; Mouterde G; Barnetche T; Lukas C; Morel J; Combe B
    Ann Rheum Dis; 2014 Feb; 73(2):414-9. PubMed ID: 23355079
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Adalimumab, etanercept, infliximab, certolizumab pegol, golimumab, tocilizumab and abatacept for the treatment of rheumatoid arthritis not previously treated with disease-modifying antirheumatic drugs and after the failure of conventional disease-modifying antirheumatic drugs only: systematic review and economic evaluation.
    Stevenson M; Archer R; Tosh J; Simpson E; Everson-Hock E; Stevens J; Hernandez-Alava M; Paisley S; Dickinson K; Scott D; Young A; Wailoo A
    Health Technol Assess; 2016 Apr; 20(35):1-610. PubMed ID: 27140438
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Effect of biologics on fatigue in psoriatic arthritis: A systematic literature review with meta-analysis.
    Reygaerts T; Mitrovic S; Fautrel B; Gossec L
    Joint Bone Spine; 2018 Jul; 85(4):405-410. PubMed ID: 29452303
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Combination therapy for pain management in inflammatory arthritis (rheumatoid arthritis, ankylosing spondylitis, psoriatic arthritis, other spondyloarthritis).
    Ramiro S; Radner H; van der Heijde D; van Tubergen A; Buchbinder R; Aletaha D; Landewé RB
    Cochrane Database Syst Rev; 2011 Oct; (10):CD008886. PubMed ID: 21975788
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Cost Effectiveness of Secukinumab Versus Other Biologics and Apremilast in the Treatment of Active Psoriatic Arthritis in Germany.
    Gandjour A; Ostwald DA
    Appl Health Econ Health Policy; 2020 Feb; 18(1):109-125. PubMed ID: 31701482
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Golimumab for the treatment of psoriatic arthritis.
    Yang H; Epstein D; Bojke L; Craig D; Light K; Bruce I; Sculpher M; Woolacott N
    Health Technol Assess; 2011 May; 15 Suppl 1():87-95. PubMed ID: 21609657
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Secukinumab in United States Biologic-Naïve Patients With Psoriatic Arthritis: Results From the Randomized, Placebo-Controlled CHOICE Study.
    Nguyen T; Churchill M; Levin R; Valenzuela G; Merola JF; Ogdie A; Orbai AM; Scher JU; Kavanaugh A; Kianifard F; Rollins C; Calheiros R; Chambenoit O
    J Rheumatol; 2022 Aug; 49(8):894-902. PubMed ID: 35428722
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Improvement in work productivity among psoriatic arthritis patients treated with biologic or targeted synthetic drugs: a systematic literature review and meta-analysis.
    Gossec L; Humphries B; Rutherford M; Taieb V; Willems D; Tillett W
    Arthritis Res Ther; 2024 Feb; 26(1):50. PubMed ID: 38360699
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Clinical efficacy, radiographic and safety findings through 2 years of golimumab treatment in patients with active psoriatic arthritis: results from a long-term extension of the randomised, placebo-controlled GO-REVEAL study.
    Kavanaugh A; McInnes IB; Mease PJ; Krueger GG; Gladman DD; van der Heijde D; Mudivarthy S; Xu W; Mack M; Xu Z; Beutler A
    Ann Rheum Dis; 2013 Nov; 72(11):1777-85. PubMed ID: 23161902
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Treatment Patterns Among Patients with Psoriatic Arthritis Treated with a Biologic in the United States: Descriptive Analyses from an Administrative Claims Database.
    Walsh JA; Adejoro O; Chastek B; Palmer JB; Hur P
    J Manag Care Spec Pharm; 2018 Jul; 24(7):623-631. PubMed ID: 29952704
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Treating to target in psoriatic arthritis: how to implement in clinical practice.
    Coates LC; Helliwell PS
    Ann Rheum Dis; 2016 Apr; 75(4):640-3. PubMed ID: 26672066
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Treatment of psoriatic arthritis with traditional DMARD's and novel therapies: approaches and recommendations.
    Maharaj AB; Chandran V
    Expert Rev Clin Immunol; 2017 Apr; 13(4):319-331. PubMed ID: 27826996
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Network Meta-Analysis of Tofacitinib, Biologic Disease-Modifying Antirheumatic Drugs, and Apremilast for the Treatment of Psoriatic Arthritis.
    Gladman DD; Orbai AM; Gomez-Reino J; Chang-Douglass S; Leoncini E; Burton HE; Kanik KS; Romero AB; Cappelleri JC; Hsu MA
    Curr Ther Res Clin Exp; 2020; 93():100601. PubMed ID: 32983284
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 29.